mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius  mpm capital back to press may   san francisco–business wire–mpm capital announces the appointment of former president of onyx pharmaceuticals pablo j cagnoni md as managing director md in addition to serving as an mpm md dr cagnoni is a cofounder of vesuvius an mpmfounded cancer immunotherapy company and has taken on the role of president and chief executive officer “pablo brings tremendous operating and clinical development expertise to mpm capital and its portfolio of investee companies developing breakthrough products” over of the course of his career as an oncologist and pharmaceutical executive dr cagnoni has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases he has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blinctyo® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® and tasigna® among them “pablo brings tremendous operating and clinical development expertise to mpm capital and its portfolio of investee companies developing breakthrough products” said luke evnin mpm capital managing director and cofounder “we feel honored and gratified that pablo chose mpm and our portfolio company vesuvius as the best platform for him to continue his significant contributions to the development of innovative oncology medicines” “mpm’s worldclass team has already demonstrated great success in the area of immunooncology with investments such as costim i am confident that vesuvius with its distinguished scientific advisory board and scientificallyrenowned cofounders is poised to develop equally innovative breakthrough therapies” said dr cagnoni as president of onyx pharmaceuticals dr cagnoni had global strategic oversight and accountability of the business from early product development to commercialization at the time of his departure onyx was on track to deliver yearly revenues in excess of b and had over  employees dr cagnoni joined onyx in march  as executive vice president global research and development and technical operations and was named president in october  when onyx became an amgen subsidiary previously he was senior vice president and global head of clinical development at novartis oncology where he was responsible for all clinical development clinical operations clinical pharmacology and correlative sciences activities for the oncology development pipeline from  to  dr cagnoni was senior vice president and chief medical officer at allos therapeutics and prior to that chief medical officer of osi pharmaceuticals earlier in his career he served as assistant professor of medicine university of colorado bone marrow transplant program where he cared for patients undergoing stem cell transplant dr cagnoni earned his medical degree from university of buenos aires school of medicine and he completed his fellowship in hematology and oncology in mount sinai medical center new york and a fellowship in stem cell transplantation at the university of colorado health sciences center about mpm capital — mpm capital httpwwwmpmcapitalcom is a global leader in earlystage life sciences venture investing with a track record of success in building worldclass companies around transformational treatments and cures with its deep experience dedicated team of operating executives and distinguished msab mpm capital is powering medical breakthroughs that change lives contacts for further information mpm capital sarah reed  sreedmpmcapitalcom x x x pablo j cagnoni md executive profile  biography  bloomberg july    pm et biotechnology company overview of tizona therapeutics inc snapshotpeople  overviewboard memberscommittees executive profile pablo j cagnoni mdcofounder chief executive officer president and director tizona therapeutics incagetotal calculated compensationthis person is connected to  board members in  different organizations across  different industriessee board relationships background dr pablo j cagnoni md is cofounder chief executive officer and president of tizona therapeutics inc he is the executive chairman of blade therapeutics he served as a managing director at mpm capital since may   he served as the president of onyx pharmaceuticals inc since october  where he had global strategic oversight and accountability of the business from early product development to commercialization of the onyx portfolio dr cagnoni joined  onyx in march  he served as an executive vice president of global research  development and technical operations at onyx pharmaceuticals inc since march  at onyx he had global strategic oversight and accountability of the business from early product development to commercialization previously he was senior vice president and global head of clinical development at novartis oncology where he was responsible for all clinical development clinical operations clinical pharmacology and correlative sciences activities for the oncology development pipeline he served as the chief medical officer and senior vice president of allos therapeutics inc from march   to september   he led allos therapeutics incs clinical development functions including clinical operations medical affairs and biometrics from  to  he held several key management positions with osi pharmaceuticals inc served as the chief medical officer and vice president of clinical research and medical affairs since december   he oversaw all of the clinical development and medical affairs activities of osi pharmaceuticalss oncology portfolio which includes further development of its flagship product tarceva he has almost  years of clinical development experience in oncology in both the biotechnology and the academic settings he served as vice president of medical affairs clinical development and translational research of osi pharmaceuticals inc and served as an interim senior medical officer for oncology clinical development since may   he served as allos therapeutics incs consultant for clinical development and regulatory activities since august  he served at allos therapeutics inc as vice president of clinical development from march  to august  and served as senior medical director from june  to february  and as a director of clinical development from july  to june  prior to allos therapeutics inc he served as an assistant professor of medicine in the division of oncology at the university of colorado where he also served as an assistant director of the pharmacology laboratory and member of the bone marrow transplant program and a member of the university of colorado cancer center he has been a director of lycera corp since march   dr cagnoni serves as a director of harpoon therapeutics he has been an independent director of crispr therapeutics ag since december  he also serves as a director of tizona therapeutics inc he has authored over  publications numerous book chapters and has lectured extensively in several areas related to clinical oncology and drug development he has year career as an oncologist and biopharmaceutical innovatorover of the course of his career dr cagnoni has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blincyto® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® tasigna® and zykadia® among them dr cagnoni earned his md from the university buenos aires school of medicine and he completed his fellowship in hematology and oncology at the mount sinai medical center new york and in bone marrow transplantation at the university of colorado dr cagnoni completed a fellowship in stem cell transplantation at the university of colorado health sciences center he graduated summa cum laude from the university of buenos aires medical schoolread full background corporate headquarters  gateway boulevardsouth san francisco california united statesphone fax  board members memberships cofounder chief executive officer president and directortizona therapeutics incpresentindependent directorcrispr therapeutics agpresentdirectorlycera corp education md universidad de buenos aires other affiliations mpm capitalallos therapeutics inconyx pharmaceuticals incosi pharmaceuticals incuniversidad de buenos aireslycera corpcrispr therapeutics ag annual compensation there is no annual compensation data available stocks options there is no stock options data available total compensation there is no total compensation data available request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup competitor compensationthere is no competitor compensation data available sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact tizona therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius  business wire mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius may    am eastern daylight time san franciscobusiness wirempm capital announces the appointment of former president of onyx pharmaceuticals pablo j cagnoni md as managing director md in addition to serving as an mpm md dr cagnoni is a cofounder of vesuvius an mpmfounded cancer immunotherapy company and has taken on the role of president and chief executive officer over of the course of his career as an oncologist and pharmaceutical executive dr cagnoni has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases he has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blinctyo® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® and tasigna® among them “pablo brings tremendous operating and clinical development expertise to mpm capital and its portfolio of investee companies developing breakthrough products” said luke evnin mpm capital managing director and cofounder “we feel honored and gratified that pablo chose mpm and our portfolio company vesuvius as the best platform for him to continue his significant contributions to the development of innovative oncology medicines” “mpm’s worldclass team has already demonstrated great success in the area of immunooncology with investments such as costim i am confident that vesuvius with its distinguished scientific advisory board and scientificallyrenowned cofounders is poised to develop equally innovative breakthrough therapies” said dr cagnoni as president of onyx pharmaceuticals dr cagnoni had global strategic oversight and accountability of the business from early product development to commercialization at the time of his departure onyx was on track to deliver yearly revenues in excess of b and had over  employees dr cagnoni joined onyx in march  as executive vice president global research and development and technical operations and was named president in october  when onyx became an amgen subsidiary previously he was senior vice president and global head of clinical development at novartis oncology where he was responsible for all clinical development clinical operations clinical pharmacology and correlative sciences activities for the oncology development pipeline from  to  dr cagnoni was senior vice president and chief medical officer at allos therapeutics and prior to that chief medical officer of osi pharmaceuticals earlier in his career he served as assistant professor of medicine university of colorado bone marrow transplant program where he cared for patients undergoing stem cell transplant dr cagnoni earned his medical degree from university of buenos aires school of medicine and he completed his fellowship in hematology and oncology in mount sinai medical center new york and a fellowship in stem cell transplantation at the university of colorado health sciences center about mpm capital  mpm capital httpwwwmpmcapitalcom is a global leader in earlystage life sciences venture investing with a track record of success in building worldclass companies around transformational treatments and cures with its deep experience dedicated team of operating executives and distinguished msab mpm capital is powering medical breakthroughs that change lives contacts for further informationmpm capitalsarah reed sreedmpmcapitalcom contacts for further informationmpm capitalsarah reed sreedmpmcapitalcom search advanced news search advanced news search log in sign up crispr therapeutics adds pablo j cagnoni md to board of directors and names tony coles md chairman of the board to enhance drug development and commercialization expertise  business wire crispr therapeutics adds pablo j cagnoni md to board of directors and names tony coles md chairman of the board to enhance drug development and commercialization expertise download full size small preview thumbnail crispr therapeutics adds pablo j cagnoni md to board of directors photo business wire paginationprevious paginationnext crispr therapeutics adds pablo j cagnoni md to board of directors photo business wire full size small preview thumbnail crispr therapeutics names tony coles md chairman of the board photo business wire full size small preview thumbnail full size small preview thumbnail march    am eastern daylight time basel switzerland  cambridge massbusiness wirecrispr therapeutics a biopharmaceutical company focused on developing transformative genebased medicines for patients with serious diseases today announced the appointment of pablo j cagnoni md to its board of directors the company also named current board member tony coles md as new chairman of the board dr coles succeeds bradley bolzon md managing director of versant ventures and founding chairman since  “as pablo and tony transition into their new roles i would like to thank brad for his leadership and commitment as our chairman since inception and am very pleased he will continue guiding the company as a director” said rodger novak md chief executive officer of crispr therapeutics “pablo is an ideal addition with his deep experience in drug development translating breakthrough therapeutic approaches into highly innovative drugs for people with cancer and other debilitating diseases his experience partnering with the medical community to transform treatment paradigms will help expedite the development of novel therapeutics derived from our proprietary technology platform” during dr cagnoni’s year career as an oncologist and biopharmaceutical innovator he has played a key role in the development approval andor commercialization of several lifechanging medicines most notably tarceva® afinitor® and kyprolis® dr cagnoni who has served as managing director of mpm capital since  is currently president and chief executive officer of tizona therapeutics and executive chairman of blade therapeutics before this dr cagnoni served as president of onyx pharmaceuticals a subsidiary of amgen where he had global strategic oversight and accountability of the business from early product development to commercialization of the onyx portfolio “i am honored and excited to join crispr therapeutics’ board at a time when its technology has the potential to revolutionize the treatment of some of the world’s most intractable diseases” said dr cagnoni “crispr therapeutics has the technology scientific rigor resources worldclass team and partners necessary to realize its ambitious mission” crispr therapeutics is focused on the discovery and development of potential cures for serious diseases using its proprietary crisprcas gene editing technology the company’s multidisciplinary team of worldclass drug developers clinicians and academics is working on its own proprietary product pipeline and also partnering with some of the world’s leading pharmaceutical and biotechnology companies to translate this technology into breakthrough human therapeutics the foundational crisprcas patent estate for human therapeutic use was licensed from scientific founder emmanuelle charpentier phd crispr therapeutics recently entered into substantial strategic partnerships with vertex pharmaceuticals and bayer prior to his tenure at onyxamgen dr cagnoni served in executive global development roles at novartis oncology allos therapeutics acquired by spectrum pharmaceuticals and osi pharmaceuticals acquired by astellas dr cagnoni earned his medical degree from the university of buenos aires school of medicine and completed his fellowships in hematology and oncology at mount sinai medical center in new york and in stem cell transplantation at the university of colorado health sciences center before joining industry he served as assistant professor of medicine at the university of colorado bone marrow transplant program dr coles joined the board of directors of crispr therapeutics in december  and currently serves as chairman and chief executive officer of yumanity therapeutics a biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding prior to founding yumanity dr coles was chairman and chief executive officer of onyx pharmaceuticals previously he held various executive and leadership positions at nps pharmaceuticals vertex pharmaceuticals bristolmyers squibb company and merck  co crispr therapeutics is headquartered in basel switzerland with its rd operations based in cambridge massachusetts for more information please visit wwwcrisprtxcom contacts wo group for crisprjennifer paganelli jpaganelliwogroupcom release summary crispr therapeutics adds pablo j cagnoni md to board of directors and names tony coles md chairman of the board to enhance drug development and commercialization expertise social media profiles crispr therapeutics crispr therapeutics contacts wo group for crisprjennifer paganelli jpaganelliwogroupcom search advanced news search advanced news search log in sign up lycera announces the appointment of pablo j cagnoni md to the board of directors lycera announces the appointment of pablo j cagnoni md to the board of directors news provided by lycera corp mar    et share this article new york and ann arbor mich march   prnewswire  lycera corp a privately held biopharmaceutical company developing breakthrough immune modulatory medicines announced today that pablo j cagnoni md has been elected to the companys board of directors effective immediately the company also announced that timothy m mayleben will step down from his position on lyceras board pablo brings to our board an acclaimed track record in drug rd having played a key role in the development and commercialization of several lifechanging medicines for people with cancer and other debilitating diseases said paul sekhri president and ceo of lycera we believe both his experience as a clinician and his deep operational expertise will have a profound impact as we continue to advance our pipeline of innovative clinicalstage candidates pablos breadth of clinical development experience and his comprehensive understanding of the regulatory process are just two reasons why i am thrilled to have him join our board at this pivotal and exciting time for lycera mr sekhri added as we welcome pablo to the board we would also like to offer our sincere gratitude to tim mayleben for his years of dedicated service tims contributions have been important to lycera in advancing our two novel programs in the clinic entering into a strategic alliance with celgene and creating a worldclass team focused on discovering and developing new therapies in autoimmune disease and immunooncology dr cagnoni throughout his year career as an oncologist and biopharmaceutical executive has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blincyto® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® tasigna® and zykadia® dr cagnoni is president and chief executive officer of tizona therapeutics an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases prior to this role he served as president of onyx pharmaceuticals a subsidiary of amgen where he was directly responsible for the onyx portfolio from early product development through commercialization previously dr cagnoni served in executive global development roles at novartis oncology allos therapeutics acquired by spectrum pharmaceuticals and osi pharmaceuticals acquired by astellas he is also a director of crispr therapeutics and harpoon therapeutics dr cagnoni earned his medical degree from the university of buenos aires school of medicine and completed his fellowships in hematology and oncology at mount sinai medical center in new york and in stem cell transplantation at the university of colorado health sciences center before joining the biopharma industry he served as assistant professor of medicine at the university of colorado bone marrow transplant program lycera has built a worldclass rd engine with an innovative clinicalstage pipeline that is addressing some of the most pressing needs in cancer and autoimmune diseases today said dr cagnoni joining the board of directors and working alongside the impressive team at lycera is an incredible opportunity to help accelerate the companys broad pipeline about lycera lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer based on successful progress of its worldclass rd platform including expertise in immune metabolism cell signaling and immune cell differentiation lycera commenced multiple clinical programs in  the company is advancing a wholly owned oral gutdirected atpase modulator designated lycec for the treatment of autoimmune disease and has entered phase  clinical studies in patients with ulcerative colitis and psoriasis a second product candidate lyc an oral rorgamma agonist has progressed into phase a testing in patients with advanced solid tumors lycera has an exclusive strategic collaboration with celgene corporation to advance lyceras proprietary pipeline for cancer and immunemediated diseases in addition lycera had previously established collaborations with merck to discover develop and commercialize small molecule therapies for autoimmune disorders lyceras leadership possesses deep experience in drug discovery development and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide lycera was founded in  based on an initial scientific platform inlicensed from the university of michigan lead investors in lycera include interwest partners arch venture partners clarus ventures and edf ventures contact justin jackson burns mcclellan  ext  jjacksonburnsmccom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleaseslyceraannouncestheappointmentofpablojcagnonimdtotheboardofdirectorshtml source lycera corp related links httpwwwlyceracom jan    et preview lycera announces initiation of phase a study argon of immunooncology candidate lyc in patients with advanced solid tumors my news release contains wide tables view fullscreen you just read lycera announces the appointment of pablo j cagnoni md to the board of directors news provided by lycera corp mar    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search pablo cagnoni  tizona therapeutics inc  zoominfocom lycera announces the appointment of pablo j cagnoni md to the board of directors – lycera lycera announces the appointment of pablo j cagnoni md to the board of directors   mar   new york and ann arbor mich mar   prnewswire — lycera corp a privately held biopharmaceutical company developing breakthrough immune modulatory medicines announced today that pablo j cagnoni md has been elected to the company’s board of directors effective immediately the company also announced that timothy m mayleben will step down from his position on lycera’s board “pablo brings to our board an acclaimed track record in drug rd having played a key role in the development and commercialization of several lifechanging medicines for people with cancer and other debilitating diseases” said paul sekhri president and ceo of lycera “we believe both his experience as a clinician and his deep operational expertise will have a profound impact as we continue to advance our pipeline of innovative clinicalstage candidates pablo’s breadth of clinical development experience and his comprehensive understanding of the regulatory process are just two reasons why i am thrilled to have him join our board at this pivotal and exciting time for lycera” mr sekhri added “as we welcome pablo to the board we would also like to offer our sincere gratitude to tim mayleben for his years of dedicated service tim’s contributions have been important to lycera in advancing our two novel programs in the clinic entering into a strategic alliance with celgene and creating a worldclass team focused on discovering and developing new therapies in autoimmune disease and immunooncology” dr cagnoni throughout his year career as an oncologist and biopharmaceutical executive has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blincyto® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® tasigna® and zykadia® dr cagnoni is president and chief executive officer of tizona therapeutics an immunology company that is harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases prior to this role he served as president of onyx pharmaceuticals a subsidiary of amgen where he was directly responsible for the onyx portfolio from early product development through commercialization previously dr cagnoni served in executive global development roles at novartis oncology allos therapeutics acquired by spectrum pharmaceuticals and osi pharmaceuticals acquired by astellas he is also a director of crispr therapeutics and harpoon therapeutics dr cagnoni earned his medical degree from the university of buenos aires school of medicine and completed his fellowships in hematology and oncology at mount sinai medical center in new york and in stem cell transplantation at the university of colorado health sciences center before joining the biopharma industry he served as assistant professor of medicine at the university of colorado bone marrow transplant program “lycera has built a worldclass rd engine with an innovative clinicalstage pipeline that is addressing some of the most pressing needs in cancer and autoimmune diseases today” said dr cagnoni “joining the board of directors and working alongside the impressive team at lycera is an incredible opportunity to help accelerate the company’s broad pipeline” about lycera lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer based on successful progress of its worldclass rd platform including expertise in immune metabolism cell signaling and immune cell differentiation lycera commenced multiple clinical programs in  the company is advancing a wholly owned oral gutdirected atpase modulator designated lycec for the treatment of autoimmune disease and has entered phase  clinical studies in patients with ulcerative colitis and psoriasis a second product candidate lyc an oral rorgamma agonist has progressed into phase a testing in patients with advanced solid tumors lycera has an exclusive strategic collaboration with celgene corporation to advance lycera’s proprietary pipeline for cancer and immunemediated diseases in addition lycera had previously established collaborations with merck to discover develop and commercialize small molecule therapies for autoimmune disorders lycera’s leadership possesses deep experience in drug discovery development and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide lycera was founded in  based on an initial scientific platform inlicensed from the university of michigan lead investors in lycera include interwest partners arch venture partners clarus ventures and edf ventures contact justin jackson burns mcclellan  ext  jjacksonburnsmccom   mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius menu menu home optical networking virtualization hyperscale data centers enews contact us rss feeds transforming network infrastructure industry news may   mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius mpm capital announces the appointment of former president of onyx pharmaceuticals pablo j cagnoni md as managing director md in addition to serving as an mpm md dr cagnoni is a cofounder of vesuvius an mpmfounded cancer immunotherapy company and has taken on the role of president and chief executive officer over of the course of his career as an oncologist and pharmaceutical executive dr cagnoni has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases he has played a key role in the development approval andor commercialization of several lifechanging medicines including afinitor® blinctyo® exjade® folotyn® glivec® jakavi® kyprolis® signifor® tarceva® and tasigna® among them pablo brings tremendous operating and clinical development expertise to mpm capital and its portfolio of investee companies developing breakthrough products said luke evnin mpm capital managing director and cofounder we feel honored and gratified that pablo chose mpm and our portfolio company vesuvius as the best platform for him to continue his significant cotributions to the development of innovative oncology medicines mpms worldclass team has already demonstrated great success in the area of immunooncology with investments such as costim i am confident that vesuvius with its distinguished scientific advisory board and scientificallyrenowned cofounders is poised to develop equally innovative breakthrough therapies said dr cagnoni as president of onyx pharmaceuticals dr cagnoni had global strategic oversight and accountability of the business from early product development to commercialization at the time of his departure onyx was on track to deliver yearly revenues in excess of b and had over  employees dr cagnoni joined onyx in march  as executive vice president global research and development and technical operations and was named president in october  when onyx became an amgen subsidiary previously he was senior vice president and global head of clinical development at novartis oncology where he was responsible for all clinical development clinical operations clinical pharmacology and correlative sciences activities for the oncology development pipeline from  to  dr cagnoni was senior vice president and chief medical officer at allos therapeutics and prior to that chief medical officer of osi pharmaceuticals earlier in his career he served as assistant professor of medicine university of colorado bone marrow transplant program where he cared for patients undergoing stem cell transplant dr cagnoni earned his medical degree from university of buenos aires school of medicine and he completed his fellowship in hematology and oncology in mount sinai medical center new york and a fellowship in stem cell transplantation at the university of colorado health sciences center about mpm capital  mpm capital httpwwwmpmcapitalcom is a global leader in earlystage life sciences venture investing with a track record of success in building worldclass companies around transformational treatments and cures with its deep experience dedicated team of operating executives and distinguished msab mpm capital is powering medical breakthroughs that change lives view source version on businesswirecom httpwwwbusinesswirecomnewshomeen  back to transforming network infrastructures homepage  home click here to share your opinion  has your company evaluated how to integrate ai artificial intelligence into your operations workstreams featured blog entries day  at interop itx  the final day we had an eventful week exhibiting at interop itx after lots of great conversations a wellattended presentation by our ceo mh raza about automating the physical layer and a wealth of different answers to our survey questions its time to travel home to connecticut first though heres a roundup of day  day  at interop itx  top of the stretch the middle and longest day was filled with fiber mountain sponsored an interop itx theater presentation on wednesday  delivered by mh raza fiber mountain ceo entitled automating the physical layer the audience was standing room only and several attendees came to our booth immediately after the presentation and learned more about the glass core and were off at interop itx  we are back in las vegas this time at interop itx  the rejuvenated version of interop as i have written in the past interop has a long history back to the mids and has reinvented itself many times interop itx  is the newest edition with only paid attendees and no more free passes to the expo floor ubm the owner of interop intends to increase the quality of attendees sessions and leads for exhibitors and sponsors industry news   webinar announced how to know if your cloud decision is right for your smb    global  billion hyperscale data center market analysis  trends     the cran centralized radio access network ecosystem     opportunities challenges strategies  forecasts    global itasaservice market  analysistechnologies  forecasts to   key players are bmc software hpe ibm red hat  vmware  request unsuccessful incapsula incident id